Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Cholangiocarcinoma × ivosidenib × Clear all

Phase

Status

Recruiting 2 Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 2 Glioma 2 Recurrence 1 Neoplasms, Unknown Primary 1 IDH1 Mutation Myeloid Neoplasms 1 Cholangiocarcinoma 1

Interventions

Gemcitabine 34 Cisplatin 20 Oxaliplatin 14 pembrolizumab 11 Capecitabine 11 Fluorouracil 8 Leucovorin 7 Radiofrequency Ablation 6 lenvatinib 5 Panitumumab 5 Bevacizumab 5 Albumin-Bound Paclitaxel 5 durvalumab 4 Nivolumab 4 Irinotecan 4 130-nm albumin-bound paclitaxel 4 tremelimumab 3 Taxes 3 Injections 3 Hepatectomy 3 Drug Therapy 3 trametinib 2 spartalizumab 2 sintilimab 2 pemigatinib 2 derazantinib 2 budigalimab 2 atezolizumab 2 apatinib 2 Stents 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02989857 2024-08-20

ClarIDHy

Servier

Phase 3 Completed

187 enrolled 34 charts 1 FDA

Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡